Campuses:
What's Inside

HOT Home

University of Minnesota Physicians Clinic Appointment and Referral Information
  Home > Faculty > Mark Reding, M.D.
 

Mark Reding, M.D.

Associate ProfessorDOMHOT_Faculty_Reding09

Director, Center for Bleeding and Clotting Disorders


Mailing Address:
Medicine - Hematology Oncology and Transplantation Office
Mayo Mail Code 480
420 Delaware Street SE
Minneapolis, MN 55455

Phone: (612) 624-0123, (612) 626-6455
Fax: (612) 625-6919
Email: redin002@umn.edu

Areas of Expertise

  • Bleeding and Clotting Disorders
  • Hemophilia
  • Benign Hematology
     
Biography
Dr. Reding received his M.D. in 1992 from the University of Minnesota. He also completed residency training in Internal Medicine and subspecialty training in Hematology/Oncology at the University of Minnesota. He is board certified in both Hematology and Medical Oncology.
 
Research Interests
Dr. Reding’s clinical interest is the treatment of non-malignant hematologic disorders, with particular emphasis on disorders of hemostasis and thrombosis, including hemophilia. His current research efforts focus on the immune response to factor VIII, the cellular mechanisms involved in the synthesis of factor VIII inhibitors, and the immunologic consequences of gene therapy.
 
Selected Publications
Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Christie BA, Key NS, Conti-Fine BM. Sensitization of CD4+ T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84:643-652.

Wu H, Reding MT, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW, Conti-Fine BM. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-133.

Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti-factor VIII subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88:568-575.

Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 2003; 1:1777-1784.

Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII. J Thromb Haemost 2004; 2:1385-1394.

Ashrani AA, Reding MT, Shet A, Osip J, Humar A, Lake JR, Key NS. Successful liver transplantation in a patient with severe haemophilia A and a high-titre factor VIII inhibitor. Haemophilia 2004; 10(6):735-737.

Reding MT. Immunological aspects of inhibitor development. Haemophilia 2006 Dec; 12(Suppl 6):30-6.

Berntorp E, Shapiro A, Astermark J, Blanchette VS, Collins PW, Dimichele D, Escuriola C, Hay CR, Hoots, WK, Leissinger CA, Negrier C, Oldenburg J, Peerlinck K, Reding MT, Hart C. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006 Dec; 12(Suppl 6):1-7.

Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia 2008; 3:36-42.

Kren BT, Unger GM, Sjeklocha L, Trossen AA, Korman V, Diethelm-Okita BM, Reding MT, Steer CJ. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest. 2009 Jul;119(7):2086-99.

Adams JE, Reding MT.  Hemophilic arthropathy of the elbow.  Hand Clin. 2011 May;27(2):151-63.

Valentino LA, Walsh CE, Reding MT, Young GA, Levendoglu-Tugal O, Cooper DL. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).  Haemophilia. 2012 Feb 20. doi: 10.1111/j.1365-2516.2012.02762.x. [Epub ahead of print]

 

Feedback | Notice of Privacy Practices


Return to: Department of Medicine: Medical School: Academic Health Center: U of M Home